Antidiabetic Activity of Bioactive Compounds in <i>Pleurotus florida</i> using Protein Receptors

Abstract

Diabetes Mellitus (DM) is a chronic metabolic disorder due to the defects of insulin secretion (type 1) and increased cellular resistance to insulin (type 2). Mushrooms were found to be effective for reducing diabetic complications and for decreasing the blood glucose levels. When compared to synthetic drugs, the bioactive compounds isolated from mushrooms seem to be less toxic and free of side effects. The ethanol extracts of Pleurotus florida mushroom was used for the extraction of bioactive compounds. The compounds PFEE-1 to PFEE -14 were screened for drug likeness and molecular properties. For structural molecular biology and computer -assisted drug design, molecular docking is found to be a strong tool. It has been used in an attempt to identify and to expound the mechanism of action of the bioactive compounds in Pleurotus florida with the inhibition of GPCR40, PTPBI, PPAR and DPP4 protein receptor for controlling the blood sugar level. 14 bioactive compounds screened from Pleurotus florida mushroom ethanol extract was docked with the glide software based on the drug-likeness score. Ergosterol was found to be a potent inhibitor of DPP4, GPCR40, PPAR and PTPBI when compared to other bioactive compounds.